A single center Phase II study for the safety and efficacy of upfront high dose chemotherapy with thiotepa and busulfan followed by autologous peripheral blood stem cell transplantation for primary central nervous system lymphoma.
Phase 2
Recruiting
- Conditions
- primary central nervous system lymphoma
- Registration Number
- JPRN-UMIN000041182
- Lead Sponsor
- Ogaki municipal hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)Other treatment for the management of underlying disease within 20 days prior to treatment initiation. 2)Patients with previous HSCT within 6 months prior to the study HSCT. 3)Patients with serious hypersensitivity to thiotepa or busulfan. 4)Patients with active infection. 5)Patients with positive test for hepatitis B surface antigen, HBV-DNA, hepatitis C virus antibody, or HIV. 6)Patients with cardiac effusion, pleural effusion, or ascites requiring treatment. 7)Patients with active double cancer. 8)Pregnant or lactating patients. 9)Patients who the investigator or subinvestigator judged as inappropriate for trial entry.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method